Drug Trial Radar · NCT07326371
Glofitamab Combined With CAR-T Therapy in R/R DLBCL
Last checked: Nov 19, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Mar 2026
Primary completion
Jul 2027
Study completion Mar 2029
Sponsor
- Lead sponsor
- Ruijin HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a single-center, open-label, prospective study aimed at evaluating the efficacy and safety of Glofitamab combined with CAR-T therapy in patients with high-risk relapsed/refractory large B-cell lymphoma.
Conditions
- DLBCL - Diffuse Large B Cell Lymphoma
Interventions
GlofitamabDrug
Glofitamab IV infusion will be administered as per the schedule specified in the respective arm.
ObinutuzumabDrug
Obinutuzumab IV infusion will be administered as per the schedule specified in the respective arm.
Axicabtagene CiloleucelDrug
Axicabtagene Ciloleucel IV infusion will be administered as per the schedule specified in the respective arm.
Relmacabtagene autoleucel (relma-cel)Drug
Relmacabtagene autoleucel IV infusion will be administered as per the schedule specified in the respective arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete Response Rate (CRR)Time frame: Baseline up to the end of treatment (EOT) (approximately 4 months)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.